Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Afprøvning af tilføjelsen af ​​et lægemiddel mod kræft, ZEN003694, til den sædvanlige kemoterapibehandling (Capecitabin) for metastaserende eller ikke-operable kræftformer

27. oktober 2026 opdateret af: National Cancer Institute (NCI)

Fase I forsøg med ZEN003694 (ZEN-3694) i kombination med Capecitabin hos patienter med solide tumorer

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.

II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.

III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).

IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.

OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.

Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Irvine, California, Forenede Stater, 92612
        • Rekruttering
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Kontakt:
        • Ledende efterforsker:
          • Fa-Chyi Lee
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Fa-Chyi Lee
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • Rekruttering
        • UF Health Cancer Institute - Gainesville
        • Kontakt:
        • Ledende efterforsker:
          • Thomas J. George
    • Illinois
      • Shiloh, Illinois, Forenede Stater, 62269
        • Aktiv, ikke rekrutterende
        • Memorial Hospital East
    • Kansas
      • Fairway, Kansas, Forenede Stater, 66205
        • Rekruttering
        • University of Kansas Clinical Research Center
        • Kontakt:
        • Ledende efterforsker:
          • Joaquina C. Baranda
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Joaquina C. Baranda
      • Westwood, Kansas, Forenede Stater, 66205
        • Rekruttering
        • University of Kansas Hospital-Westwood Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Joaquina C. Baranda
    • Missouri
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Aktiv, ikke rekrutterende
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Aktiv, ikke rekrutterende
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Forenede Stater, 63110
        • Aktiv, ikke rekrutterende
        • Washington University School of Medicine
      • St Louis, Missouri, Forenede Stater, 63129
        • Aktiv, ikke rekrutterende
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Forenede Stater, 63136
        • Aktiv, ikke rekrutterende
        • Siteman Cancer Center at Christian Hospital
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Ledende efterforsker:
          • Ryan Moy
        • Kontakt:
      • The Bronx, New York, Forenede Stater, 10461
        • Rekruttering
        • Montefiore Medical Center-Einstein Campus
        • Kontakt:
        • Ledende efterforsker:
          • Chaoyuan Kuang
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Montefiore Medical Center - Moses Campus
        • Kontakt:
        • Ledende efterforsker:
          • Chaoyuan Kuang
      • The Bronx, New York, Forenede Stater, 10461
        • Rekruttering
        • Montefiore Medical Center-Weiler Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Chaoyuan Kuang
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • Rekruttering
        • University of Cincinnati Cancer Center-UC Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Davendra P. Sohal
      • West Chester, Ohio, Forenede Stater, 45069
        • Rekruttering
        • University of Cincinnati Cancer Center-West Chester
        • Kontakt:
        • Ledende efterforsker:
          • Davendra P. Sohal
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Ledende efterforsker:
          • Susanna V. Ulahannan
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Rekruttering
        • UPMC Hillman Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Ledende efterforsker:
          • Anwaar Saeed
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University/Ingram Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-811-8480
        • Ledende efterforsker:
          • Thatcher R. Heumann
      • Nashville, Tennessee, Forenede Stater, 37204
        • Rekruttering
        • Vanderbilt Breast Center at One Hundred Oaks
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-811-8480
        • Ledende efterforsker:
          • Thatcher R. Heumann

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
  • Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
  • Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
  • Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
  • Patients must have measurable disease
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
  • Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
  • Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
  • Absolute neutrophil count >= 1,000/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
  • Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients should be New York Heart Association Functional Classification of class 2B or better
  • The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion Criteria:

  • Previous treatment with BET inhibitors
  • History of inability to tolerate capecitabine at the projected treatment dose on this trial
  • Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
  • Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
  • Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
  • Hepatic tumor burden > 30% or peritoneal carcinomatosis
  • Untreated/uncontrolled central nervous system (CNS) disease
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Severe intercurrent illness or comorbidity
  • Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
  • Patients who are receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
  • Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment (ZEN003694, capecitabine)

Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

Undergo MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Undergo biopsy

Andre navne:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Undergo collection of blood samples

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Undergo PET/CT

Andre navne:
  • Medicinsk billeddannelse, Positron Emission Tomografi
  • KÆLEDYR
  • PET-scanning
  • Positron Emission Tomografi Scan
  • Positron-emissionstomografi
  • PT
  • Positron emissionstomografi (procedure)

Given PO

Andre navne:
  • Xeloda
  • Ro 09-1978/000

Given PO

Andre navne:
  • BETi ZEN-3694
  • ZEN 3694
  • ZEN-3694
  • ZEN003694

Undergo CT and PET/CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of adverse events
Tidsramme: Up to 30 days after last dose

Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.

Up to 30 days after last dose
Maximum tolerated dose (MTD)
Tidsramme: During the first cycle of therapy (Cycles = 21 days)

Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD.

During the first cycle of therapy (Cycles = 21 days)
Recommended phase 2 dose (RP2D)
Tidsramme: Up to 30 days after last dose

Dose level 4 was selected as the RP2D.

Up to 30 days after last dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
Tidsramme: Up to 12 months

Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD.

Up to 12 months
Progression free survival (PFS)
Tidsramme: Up to 12 months

PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions.

Up to 12 months
Objective response rate (ORR)
Tidsramme: Up to 12 months

Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals.

Up to 12 months
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
Tidsramme: Up to 12 months

Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data.

Up to 12 months
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
Tidsramme: Up to 12 months

Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05.

Up to 12 months
Molecular subpopulations particularly sensitized to BETi and capecitabine
Tidsramme: Up to 12 months

Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity.

Up to 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Anwaar Saeed, University of Pittsburgh Cancer Institute LAO

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. november 2023

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

6. april 2023

Først indsendt, der opfyldte QC-kriterier

6. april 2023

Først opslået (Faktiske)

7. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NCI-2023-02652
  • UM1CA186690 (U.S. NIH-bevilling/kontrakt)
  • 10579 (Anden identifikator: CTEP)
  • NCI-2023-02652 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • HCC 23-096
  • 10579 (Anden identifikator: UPMC Hillman Cancer Center LAO)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .